The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.

Abstract

BACKGROUND:

Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20-30% of patients relapse. Salvage CT options include conventional (CDCT) and high dose chemotherapy (HDCT), however definitive comparative data remain lacking. We aimed to characterize the contemporary practice patterns of salvage CT across Canada.

METHODS:

We conducted a 30-question online survey for Canadian medical and hematological oncologists with experience in treating GCT, assessing treatment availability, patient selection, and management strategies used for relapsed GCT patients.

RESULTS:

There were 30 respondents from 18 cancer centers across eight provinces. The most common CDCT regimens used were TIP (64%) and VIP (25%). HDCT was available in 13 centers (70%). The HDCT regimen used included carboplatin and etoposide for two cycles (76% in 7 centers), three cycles (6% in 2 centers), and the TICE protocol (11%, in 2 centers). "Bridging" CDCT was used by 65% of respondents. Post-HDCT treatments considered include surgical resection for residual disease (87.5%), maintenance etoposide (6.3%), and surveillance only (6.3%).

CONCLUSIONS:

HDCT is the most commonly used GCT salvage strategy in Canada. Significant differences exist in the treatment availability, selection, and delivery of HDCT, highlighting the need for standardization of care for patients with relapsed testicular GCT.

• Authors: Esmail M Al-Ezzi, Amer Zahralliyali, Aaron R Hansen, Robert J Hamilton, Michael Crump, John Kuruvilla, Lori Wood, Lucia Nappi, Christian K Kollmannsberger, Scott A North, Eric Winquist, Denis Soulières, Sebastien J Hotte, Di Maria Jiang
• Journal: Current oncology (Toronto, Ont.) (Curr Oncol) Vol. 30 Issue 7 Pg. 6166-6176 (06 27 2023) ISSN: 1718-7729 [Electronic] Switzerland
• PMID: 37504318 (Publication Type: Journal Article)

Chemical References

• Etoposide

Topics

• Male
• Humans
• Etoposide (therapeutic use)
• Prognosis
• Antineoplastic Combined Chemotherapy Protocols
• Neoplasm Recurrence, Local (drug therapy)
• Canada
• Neoplasms, Germ Cell and Embryonal (drug therapy)